Review finds strongest comparative evidence for CBD in drug-resistant epilepsy
Effectiveness, safety and therapeutic potential of medical cannabis across treatment-resistant neuropsychiatric disorders: systematic review and meta-analysis.
AI Summary
This systematic review and meta-analysis examined whether medical cannabis helps people with treatment-resistant neuropsychiatric disorders and what harms are reported. It included 127 studies, with 32 studies involving 3,645 participants contributing to the meta-analysis. The main comparative analyses found improvement in drug-resistant epilepsy, refractory pain, and multiple sclerosis spasticity. The review says the most consistent comparative evidence was for adjunctive pharmaceutical CBD reducing seizure frequency in selected drug-resistant epilepsy; evidence for pain and multiple sclerosis was more variable.
Safety findings were not uniformly reassuring: comparative analyses found higher odds of adverse events in drug-resistant epilepsy and refractory multiple sclerosis, and epilepsy analyses also found higher odds of serious adverse events and withdrawals due to adverse events. Evidence for treatment-resistant psychiatric disorders was limited: results for anxiety were inconsistent, and schizophrenia showed no reliable therapeutic effect. The authors conclude that the evidence is insufficient to support routine clinical recommendations for psychiatric disorders. As an abstract-based summary of a review, this cannot establish how well a particular formulation works for an individual condition; the authors highlight heterogeneous evidence and the need for better diagnosis- and formulation-specific studies.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.